Roche: new phase III study for Rituximab

(CercleFinance.com) - Roche today announced data from the Phase III PEMPHIX study which evaluates the efficacy and safety of MabThera/Rituxan (rituximab) versus mycophenolate mofetil (MMF) in adults with moderate-to-severe pemphigus vulgaris (PV).


The results were presented at the 28th Congress of the European Academy of Dermatology and Venereology, held in Madrid, Spain.

40% of patients with pemphigus vulgaris (PV) experienced prolonged complete remission without steroid use for 16 weeks or longer, with MabThera/Rituxan compared to 9.5% of patients receiving mycophenolate mofetil.

A study reinforces the efficacy and safety of MabThera / Rituxan for the treatment of PV, a rare autoimmune disease which is characterised by blisters on the skin and mucous membranes.

"The approval of MabThera/Rituxan for the treatment of pemphigus vulgaris was the first major advancement in the treatment of this rare, serious disease in more than 60 years," said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development.


Copyright (c) 2019 CercleFinance.com. All rights reserved.